The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy

被引:72
作者
De Meerleer, G
Villeirs, G
Bral, S
Paelinck, L
De Gersem, W
Dekuyper, P
De Neve, W
机构
[1] Ghent Univ Hosp, Dept Radiat Oncol, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Dept Radiol, B-9000 Ghent, Belgium
[3] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium
关键词
D O I
10.1016/j.radonc.2005.04.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Local relapse after radiotherapy for prostate cancer mostly originates at the original tumor location. Dose escalation reduces local relapse rates. It may be of benefit to focus the highest dose to the intraprostatic lesion (GTVMRI) using intensity-modulated radiotherapy (IMIRT). Therefore, the visualization of the GTVMRI and its inclusion into computer optimization is mandatory. Materials and methods: Fifteen patients with prostatic adenocarcinoma were referred for IMIRT. All these patients had a palpable lesion on digital rectal examination (DRE) and/or a PSA > 10.0 ng/ml. A T2-weighted MR examination of the prostate was performed in order to detect a GTVMRI and correlate the location of the GTV(MRI) with the site of the tumour-containing cylinder (biopsy). Two IMIRT plans were compared: a plan without the inclusion of the GTVMRI (IMRT-CONV) versus a plan including the GTV(MRI) into the plan optimization (IMRT-GTV(MRI)). For comparison, both physical and biological endpoints of the GTV(MRI), CTV, PTV and rectum were taken into account. After the finalization of the planning study, the IMRT-GTVMRI plans were clinically delivered using step-and-shoot IMRT. Acute gastro-intestinal (GI) and genito-urinary (GU) toxicity were recorded. Results: In all cases, the location of the GTV(MRI) corresponded with the site of the tumor containing biopsy cylinder. The mean and median distance of the GTVMRI to the anterior rectal wall was 3 and 2 mm, respectively (range: 0-12 mm). For the GTVMRI, its inclusion in the optimization led to a significant increase of all physical endpoints (P<0.01), without compromising the dose to the CTV, PTV and rectum. Mean GTV(MRI) dose was 78.3 Gy (IMRT-GTV(MRI)) versus 76.9 Gy (IMRT-CONV) (P<0.00001). All IMRT treatments were successfully delivered within 6 min. We did not observe grade 3 acute GI toxicity. One patient developed grade 3 GU toxicity (nocturia), that disappeared after administration of medication. Grade 2 GI and GU toxicity was observed in, respectively, four and six patients. Conclusion: Using T2-weighted MR, the visualization of an intraprostatic lesion is feasible. The inclusion of the GTV(MRI) into planning optimization leads to a modest increase in dose, without compromising the dose to the CTV, PTV and organs at risk. The clinical delivery of these plans runs without problems. Acute toxicity is mild. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:325 / 333
页数:9
相关论文
共 55 条
[1]   Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy [J].
Albert, M ;
Tempany, CM ;
Schultz, D ;
Chen, MH ;
Cormack, RA ;
Kumar, S ;
Hurwitz, MD ;
Beard, C ;
Tuncali, K ;
O'Leary, M ;
Topulos, GP ;
Valentine, K ;
Lopes, L ;
Kanan, A ;
Kacher, D ;
Rosato, J ;
Kooy, H ;
Jolesz, F ;
Carr-Locke, DL ;
Richie, JP ;
D'Amico, AV .
CANCER, 2003, 98 (05) :949-954
[2]  
Bartolozzi C, 1996, EUR RADIOL, V6, P339
[3]   Endorectal MRI using a 0.5T mid-field system in the staging of localized prostate cancer [J].
Bates, TS ;
Cavanagh, PM ;
Speakman, M ;
Gillatt, DA .
CLINICAL RADIOLOGY, 1996, 51 (08) :550-553
[4]   Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging [J].
Beyersdorff, D ;
Taupitz, M ;
Winkelmann, B ;
Fischer, T ;
Lenk, S ;
Loening, SA ;
Hamm, B .
RADIOLOGY, 2002, 224 (03) :701-706
[5]   Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms [J].
Boersma, LJ ;
van den Brink, M ;
Bruce, AM ;
Shouman, T ;
Gras, L ;
te Velde, A ;
Lebesque, JV .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (01) :83-92
[6]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[7]   OPTIMIZATION OF PROSTATE CARCINOMA STAGING - COMPARISON OF IMAGING AND CLINICAL METHODS [J].
BONI, RAH ;
BONER, JA ;
DEBATIN, JF ;
TRINKLER, F ;
KNONAGEL, H ;
VONHOCHSTETTER, A ;
HELFENSTEIN, U ;
KRESTIN, GP .
CLINICAL RADIOLOGY, 1995, 50 (09) :593-600
[8]   NONPALPABLE PROSTATE-CANCER - DETECTION WITH MR IMAGING [J].
CARTER, HB ;
BREM, RF ;
TEMPANY, CM ;
YANG, A ;
EPSTEIN, JI ;
WALSH, PC ;
ZERHOUNI, EA .
RADIOLOGY, 1991, 178 (02) :523-525
[9]   Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning [J].
Cellini, N ;
Morganti, AG ;
Mattiucci, GC ;
Valentini, V ;
Leone, M ;
Luzi, S ;
Manfredi, R ;
Dinapoli, N ;
Digesu', C ;
Smaniotto, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (03) :595-599
[10]   The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants [J].
Clarke, DH ;
Banks, SJ ;
Wiederhorn, AR ;
Klousia, JW ;
Lissy, JM ;
Miller, M ;
Able, AM ;
Artiles, C ;
Hindle, WV ;
Blair, DN ;
Houk, RR ;
Sheridan, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (04) :903-910